Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 15 versus ADDERALL XR 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 15 versus ADDERALL XR 30.
ADDERALL XR 15 vs ADDERALL XR 30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
None Documented
None Documented
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant